|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Bristol-Myers Squibb Company (NYSE:BMY), a global pharmaceutical and related health care products company. |
|---|---|
| Transferring Party | Adnexus™ Therapeutics, a developer of a new therapeutic class of biologics called Adnectins™. |
| Sector | Biopharmaceuticals |
| Date | September 24, 2007 |
| Analysis Advances Bristol-Myers' biologics strategy across multiple therapeutic areas and includes a Phase I oncology biologic. Adnectins are an emerging, proprietary protein therapeutic class based on human fibronectin, an extracellular protein that is naturally abundant in human serum. The deal includes Adnexus' patented protein design engine that screens trillions of unique Adnectins for each drug discovery program, greatly accelerating drug discovery and development. Deal value - $430 plus an earnout potential of $75m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |